Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NSCC Marketing Representatives are available to provide further information about the company’s systems and services, structure, fees and operations. Please contact:
National Securities Clearing Corporation
55 Water Street,51nd Floor
New York, N.Y. 10041
Tel. (212) 855-4155
Fax (212) 908-2350
www.nscc.com
Offices
National Securities Clearing Corporation
Corporate Office
55 Water Street
New York, New York 10041
(212) 412-8400
www.nscc.com
Chicago
111 West Jackson Blvd., Suite 1128
Chicago, Illinois 60604
San Francisco
425 California Street
San Francisco, California 94104
Toronto
85 Richmond Street West
Toronto, Ontario, Canada M5H 2C9
The Depository Trust & Clearing Corporation
Corporate Office
55 Water Street
New York, New York 10041
(212) 855-1000
www.dtcc.com
Government Securities Clearing Corporation
Corporate Office
55 Water Street
New York, New York 10041
(212) 412-8400
www.gscc.com
MBS Clearing Corporation
Corporate Office
55 Water Street
New York, New York 10041
(212) 412-8400
www.mbscc.com
Emerging Markets Clearing Corporation
Corporate Office
55 Water Street
New York, New York 10041
(212) 701-9700
www.e-m-c-c.com
http://www.nscc.com/factsheets/index.html
NSCC History & Structure
NSCC began operating in 1976 with the consolidation of the clearing operations of the NYSE, Amex and NASD. It was created to address the existing and evolving post-trade processing needs of broker/dealers and banks and has since expanded its services to include the mutual fund community and insurance carriers. A user-driven corporation, NSCC’s senior management is guided by its Board of Directors on policy development, operational planning and financial management.
NSCC Participants
More than 2,500 brokers, dealers, banks, mutual funds, insurance carriers and financial intermediaries currently use NSCC’s services as direct participants, or as indirect participants through correspondent relationships.
http://www.nscc.com/factsheets/index.html
National Securities Clearing Corporation (NSCC) is the nation’s leading provider of centralized clearance, settlement and information services for equity, corporate and municipal bond, Unit Investment Trust (UIT), mutual fund and annuity transactions. NSCC plays a critical role in the safety and soundness of the markets by guaranteeing trades entered into its system and netting or reducing total financial obligations. The organization also brings added efficiency through technology solutions that link manufacturers and distributors of financial products.
DNAP ** (link provided) Did you know about the: ** which indicates NSCC Eligible Security (National Securities Clearing Corporation)? These guys are doing the clearance and settlement for DNAP to be listed on the OTCbb. I do not think I have seen this link before! Here is the link, if you have not seen this too!
http://www.nscc.com/index.html
Novartis, maker of Lescol® (fluvastatin) an antihyperlipidemic drug (a statin) is another candidate for partnership with DNAP. Novartis will spend 25 to 28 percent, of their research budget toward outside partners! This includes genomics and proteomics! Since DNAP is working on statins, see http://www.dnaprint.com./index.cfm?fuseaction=content&id=24 there is the possibility of a deal between Novartis and DNAP. Especially, with Norvartis's developing and eventual marketing Lescol XL! This is the article's web address that stated that Novartis intends on investing in other genomic and proteomic companies (fifth paragraph): http://www.genomeweb.com/ type in Novartis and hit the go button. Here is the article itself!
Novartis Announces $84M Deal with Geneva Proteomics
Written By: Marian Moser Jones
NEW YORK, Oct. 17 – Swiss pharmaceutical giant Novartis has agreed to pay Geneva Proteomics $84 million to analyze the proteomes of three types of human tissues over the next five years, the companies announced Tuesday.
Novartis, based in Basel, Switzerland will make a $43 million equity investment in Geneva-based Geneva Proteomics, and will pay the proteomics company $41 million in fees over the next four years. Geneva Proteomics may also receive additional milestone payments, license fees, and other reimbursements. The fifth year of the deal includes proteomics analysis work that is yet to be determined.
“From a global perspective, this is the big deal on proteomics,” said Felix Raeber, Novartis’ communications director.
" The collaboration with GeneProt complements our in-house research activities in functional genomics and proteomics and strengthens our position as leading in the post- genomics area,” Paul Herrling, head of Novartis' pharma research, said in a statement.
Geneva proteomics is Novartis’ biggest partner in proteomics research, but the pharma company has not ruled out other proteomics partnerships. Twenty-five to 28 percent of Novartis' research budget is directed towards outside research partnerships, so further genomics and proteomics partnerships will be likely, Raeber said.
Under this agreement, Geneva Proteomics will analyze the twin proteomes of three human diseased tissues or body fluids and their healthy counterparts. Novartis will select out proteins or peptides with potential to serve as targets for lead discovery, or proteins that could serve as direct biomarkers for disease state or therapeutic efficacy.
Geneva Proteomics will be expanding its staff in the coming months so it can tackle the new task before it.
Although this partnership keeps Novartis’ business within the borders of Switzerland, Novartis says it chose Geneva Proteomics primarily for its proteomics expertise. “Geneva Proteomics’ researchers are the world’s leading experts in this field,” said Raeber. “But from a Swiss perspective, we are happy that we have the world’s leading experts in Geneva.”
Raging Bull loses its punch
by Heidi Nasr
Posted 06:54 PM EST, Dec-26-2000
When AltaVista Co. grabbed investor information Web site Raging Bull by the
horns in February for $163 million, the U.S. search engine had high hopes of
being more than an Internet portal.
Less than a year later, Palo Alto, Calif.-based AltaVista announced that it had
hired U.S. investment bank Chase H & Q to find a buyer for Raging Bull. An
AltaVista press officer said the company wants to return to its search engine
roots.
But buyers won't be easy to find, said U.S. Bancorp Piper Jaffray analyst
Safa Rashtchy, who covers AltaVista parent CMGI Inc. of Andover, Mass.
The reason: Raging Bull provides financial information and chat rooms for
individual investors, a group that is no longer as irrationally exuberant as it
was in February.
"The days of day-traders and prices jumping through the roof are over,"
Rashtchy said. Moreover, he noted that Raging Bull's business model -- a
free-content provider that relies on advertising-revenue -- is decidedly out of
favor these days.
Nonetheless, AltaVista spokesman David Emanuel remained confident. He
declined to name potential acquirers of Andover, Mass.-based Raging Bull
but said that discussions with two or three companies were "pretty serious."
Emanuel also declined to comment on a possible sale price or target date for
the sale. But he said that AltaVista hopes to find a buyer in six to eight
weeks.
Emanuel said that AltaVista will look for an acquirer with a similar strategy in
one of three categories: content companies, financial services companies
and media companies.
The scuttlebutt on the deal seems to bear out his expectations. Potential
buyers mentioned in the press after Alta Vista announced the sale over the
holiday weekend included E*Trade Group, Charles Schwab Corp. and
Ameritrade Group among the financial services companies and
TheStreet.com and MarketWatch.com on the content or media sides.
Piper Jaffray's Rashtchy said that E*Trade or Ameritrade are more likely
possibilities than Schwab, since those two companies don't have discussion
boards and would probably welcome the chance to reach out to the average
investor. Schwab's customers, in contrast, are "high-end" and not attracted to
discussion boards, Rashtchy said.
TheStreet or MarketWatch are even less likely acquirers, Rashtchy said.
"They're having troubles of their own," he said. Ameritrade, however, could
offer Raging Bull as an additional service to its existing customers, Rashtchy
said.
The "for sale" sign on Raging Bull in certainly indicative of the times. Once
the blue-eyed boy of the Internet content revolution back at its birth in late
1998, the startup attracted sizable venture capital investments from CMGI's
@Ventures and CNET.com.
The Web site had gathered awards, recognition and lavish attention from the
press when AltaVista announced it would acquire Raging Bull in late
November 1999. By the time the acquisition closed in February, however, the
market was already preparing for its coming and sustained slump in the
spring.
AltaVista, of course, paid for the acquisition amid the high-flying valuations of
late 1999, when Raging Bull commanded a $163 million all share purchase
price. Now, Rashtchy says, the purchase price will have to be "substantially
below that."
AltaVista bought Raging Bull in an all-stock deal last year. Since both
companies are privately held, it's hard to know how much their stock would
be worth today. But in the intervening months, the stock price of AltaVista's
parent, CMGI, has declined precipitously.
When AltaVista first announced it would acquire Raging Bull, CMGI stock
was trading at $155.50, close to its 52-week high of $163.50. When the
acquisition closed in February, CMGI stock was dented but still comfortable
at $124.50.
Since then, however, the market has shown no mercy. CMGI shares closed
Tuesday at just above $6.37.
Rashtchy declined to speculate on reported price ranges of around $100
million for Raging Bull. But he added: "Many of [these types of] companies
these days are going for a fairly minimal amount."
Yet disposing of Raging Bull makes sense to Rashtchy. "It is consistent with
what AltaVista wants to do," he pointed out. "They have given up on being a
portal."
http://www.ragingbull.altavista.com/mboard/boards.cgi?read=118071&board=IBUI
I got this early service, from E*trade as a promo some time back! Does everyone trading E*trade have this now?
E*TRADE's Extended Hours Trading service is available from 8:00AM - 9:30AM and
4:05PM - 6:30PM EDT only.
Does any Trade before hours using E*trade besides me?
good2bhumble glad to have you here! When we make a few thou, I would like to look into your idea next year (in more detail)!
FM, there is some excitement over a deal with two big companies! I am sure you have heard about IBM and Celera! I have an email from Craig that may shows that DNAP is indeed looking for big players! These players do not have to be big biotechs or big pharmas! DNAP wants to have someone that has marketability powers! Read this email from Craig I received on 12-01-2000!
IVRT,
Just got your message. Dr. Frudakis' presentation was very informative, however, we do not have an audio, video, or transcript of the event.
In answering your question, DNAPrint does not intend to market its own products, but rather partner with larger companies that have that ability. Also, we are not asking the doctor to substitute their drug choice for another, but to run a test before prescribing the drug to make sure that it does not cause serious side-effects. We feel that if a test is available that can determine this information, then the doctor is morally obligated to perform that test.
Regards,
Craig Hall
----- Original Message -----
From: CMAACCESS
To: Richard Craig Hall
Sent: Friday, December 01, 2000 4:23 PM
Subject: Fw: Question
Craig, I sent this to Dr. Tony and have not received a response. Can you please relay this message to him for an answer? Thanks and I hope you had a great Thanksgiving holiday too? Also, one finally note Craig, will you audio/videotape or transcript any/all of the open house tomorrow? I will not make the open house, but I am genuinely interested in the contents. Thanks!
----- Original Message -----
From: CMAACCESS
To: tfrudakis@dnaprint.com
Sent: Friday, November 24, 2000 1:06 PM
Subject: Question
Dr. Frudakis, what do you think will be your greatest tool in convincing Doctors to initially allow a platform software program, such as DNAP's to recommend, and subsequently having the doctor actually substitute his/her preferred drug choice, with DNAP's drug choice? Thanks for your answer!
IVRT
FM, let me share an email I got, from Craig on 10-31-2000! I am not sure, if you have read this one before? FM, look closely at the paragraph immediately after answer number (3) below! Craig stated that the software and near completion of the platform may be demonstrated at the March conference in SF,CA. Remember this email was dated 10/31/2000; this may answer a question that many had about the further assistance of Dr. Kim! Dr. Kim is not a biotech expert and the new doctors probably took his place on the final software and platform development and TESTING! In addition, Craig stated that Dr. Tony was to speak, not Dr. Kim!
This is speculation (hypothetical), but from Craig's email, we may deduce that the software and platform work of 10-31-2000 was over 70 percent finished then! From now until the March conference is only two months away! If we add the last two months, November and December, we are looking at four month's time, until the March 2001 conference, and that did not give DNAP much time to finish and test their software and platform! I believe software and platform (live) testing is going on now or in early 01-2001, through the statin and ovarian cancer projects, and partial results may be told at the March 2001 conference! With success, we could very well see DNAP, with revenues by the second quarter of 2001! All of this is my opinion, but we can speculate right? We will see, I have been a DNAPPER since July and I can wait!
Here is the email:
IVRT,
Here are the answers to your questions:
(1) Dr. Frudakis is presenting at the San Francisco conference.
(2) I do not know the time he is allotted at this time.
(3) It is my understanding that we will be given booth space.
In addition, by March we hope to have our software completed and be near completion on our platform. This should be our opportunity to show the scientific world that our software can draw complex associations.
Regards,
Craig Hall
----- Original Message -----
From: CMAACCESS
To: Richard Craig Hall
Sent: Monday, October 30, 2000 9:34 PM
Subject: Conference
Craig, regarding the GENOMIC PARTNERING: EMERGING AND EARLY-STAGE COMPANIES March 3-4, 2001 • The Fairmont Hotel • San Francisco, California, can you give some additional information please?
1. Will Dr. Tony will be presenting at this conference too?
2. How much time will be allotted for the DNAP presentation this time?
3. Will you guys have a poster booth this time around?
Thanks in advance and the reply! I also want to add, Craig, you are a valuable asset to your company. All of us (99.99%) that frequent the internet boards feel that you are the exception rather than the rule, when it comes to investor relations! No BS, just the facts and prompt, with your replies!
IVRT
Happy New Year to You FM! I have been in 44 states of this great USA, but have yet to set foot on Florida soil! We (the wife and I) may spend sometime in sunny Florida celebrating DNAP success next year! I thank you for the invite ... IVRT!
Happy New Year Cerealman! Next week should be one heck of DNAP party for us longs! Craig had originally told me 12-29-2000, but I would rather take profits in the new year; consequently, this listing in 2001 is just right by me!
We are on a countdown to listing, in my opinion in a matter of days and not weeks. The rest of this week should be buzzing, with excitement on all of the DNAP boards on the net and elsewhere! There are many at my job that have bought DNAP. One woman that I work said her brother-in-law bought DNAP, got so excited about DNAP he told everone on his night shift at a local papermill, and most of his fellow employees bought DNAP too!
We are all excited and I for one am ready for a prosperous new year!!!!
FM, when DNAP hits it big, we will all sit down together for a few big steaks! Thanks for the offer!!!!
Thanks Glad, you are always welcome here!
Hello FM, I am getting ready to leave the RB DNAP board for good! I will be posting my emails, from DNAP and other information I have here only! I may post what I get on SI! I know that I do not have exclusive information, but RB is getting to be a crap shoot and I believe this is the best place to post DNAP information!
Thanks for sharing the information cerealman! I am ready to see GREEEEEEEEEEEEEN $$$$$$$$$$$$$$$$$$$$$$$$ YEAH!!!!!
2001 is our year DNAPPERS!!!!!!!!!!!!!!
Thanks Stockholder101, I am ready for the fun to begin, and this week is a key to a happy 2001 for me!
DNAPrint and The University of Miami Announce Pharmacogenomics Collaboration
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DWAVO%5Cbw%5C20001213%5C15%5C200012131525COMTEX__NEWSROOMI9LOHCD9Q2QBY.html%26clientid%3D168%26provider%3DBUSINESS_WIRE&symbol=DNAP
Have you seen this new addition on DNAP's web page(s)? Statins
Hypercholesterolemic and dyslipidemic patients are at increased risk for atherosclerotic vascular (heart) disease. Currently, these patients are prescribed medications, nicknamed "statins", to ameliorate this risk. Statins function to decrease cholesterol levels by inhibiting a key enzyme (HMG-Co enzyme A reductase) in the cholesterol pathway. According to the National Heart, Lung, and Blood Institute's National Cholesterol Education Program, high cholesterol is one of the key risk factors for heart disease. Heart disease is the number one cause of death for both men and women in the United States, and more than 90 million American adults, or about 50 percent of the population, have elevated blood cholesterol levels. A study published in the New England Journal of Medicine in September 1998 says heart disease deaths have declined steadily over the last 30 years, decreasing by 10.3 percent between 1990 and 1994 alone. This improvement is largely attributable to better prevention of heart disease through the wide-spread use of statins.
Notwithstanding the efficacy of this class of drugs, individual patients respond differently to statins based on a variety of inter-individual genetic and environmental differences. About 2%-5% of patients are discontinued from statin treatment due to adverse experiences including hepatocellular toxicity (indicated by elevated serum levels of certain liver enzymes), and more rarely, Rhabdomyolysis with acute renal failure. In fact, it is recommended that physicians monitor this toxicity by performing liver function tests prior to, and at 12 weeks following, both the initiation of therapy and any elevation of dose, and periodically thereafter.
As a recent Time magazine article points out, statins may potentially serve as a useful preveltative tool to reduce the risk of heart disease in the general, healthy population. A key impediment for the expansion of the statin market in this way is the danger posed by adverse events associated with use of these drugs. For example, the long term affects of hepatocellular injury is not clearly understood.
Diagnomics products could potentially help reduce the risk associated with the use of statins in the general population. The Statin project we are conducting is expected to result in several "diagnomics" test solutions for routine patient pre-screening prior to statin prescription. Based on the prevalence of dyslipidemia and hypercholesteremia in the population, such a product could enjoy a market in excess of several billion dollars in the near future.
Copyright DNAprint genomics © 2000
1748 Independence Blvd. Ste D1
Sarasota, Florida 34234
DNAprint Genomics consultant: Robert Preston White, PA-C,
Mr White has previous experience managing complex specimen collections, having performed similar work with N.I.H. funded collections at the University of Miami School of Medicine and Mt. Sinai Medical Center in Miami Beach, FL
DNAPrint Files First Provisional Software Patent
http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%
3Ftextpath%3DWAVO%5Cbw%5C20001202%5C14%5C200012021401COMTEX__NEWSROOMDELNPNNPHGCJF.html%26clientid%3D168%26provider%3DBUSINESS_WIRE&symbol=DNAP
DNAPrint Adds Famous Biostatistician to Board of Advisors
November 22, 2000
SARASOTA, Fla., Nov 22, 2000 (BUSINESS WIRE) -- DNAPrint genomics, Inc. (Pink Sheets:DNAP) announced today that the company has added Professor DC Rao to its Scientific Advisory Board (SAB).
Dr. Rao currently serves as the Director of the Division of Biostatistics, at the Washington University in St. Louis (WUSTL). Dr. Rao has served in this role since 1980, and has been a Professor of Biostatistics since 1982. He holds joint appointments in the Departments of Psychiatry, Genetics, and Mathematics at Washington University. Additionally, Dr. Rao is a member and past president of the International Genetic Epidemiology Society (1996) and is a founding Editor-in-Chief of the society's journal, Genetic Epidemiology.
Dr. Rao is an expert in genetic epidemiology. His research in the field includes the development of new methods to analyze and model genetic data. Washington University is one of the handful of academic centers working on the Human Genome Project. His work at WUSTL focuses on the genetic dissection of complex disease traits such as coronary heart disease, obesity, hypertension, and pulmonary disease. As an experienced genetic epidemiologist, Dr. Rao is best known for his contributions to path analysis. He has published over 300 research articles in peer-reviewed journals and is considered to be one of the world's top Statistical Geneticists.
The Company recently announced the addition of another well-known Statistical Geneticist, Dr. Ponnuswamy, as a full-time Scientist and Vice-President of the Company's Department of Biostatistics. The addition of Dr. Rao to the companies SAB further strengthens the Companies expertise in this field.
About DNAPrint genomics
DNAPrint genomics, Inc. is developing complex genetic analytics and information resources for next generation personalized medicine. The company's products will provide practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. On November 3, 2000, the company announced that it had filed its form 8K and expects to be trading on the NASD OTC Bulletin Board in the next few weeks. For more information about the company, please visit www.DNAPrint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
CONTACT: DNAPrint genomics, Inc., Sarasota
For Scientific inquiries:
Tony Frudakis, Ph.D., 941/351-4543
or
Other inquiries
Richard Craig Hall, 941/341-0136
URL: http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2000 Business Wire. All rights reserved.
Top 10 ?? Suggestions:
If you are going to ask questions about DNAP's business, then please leave TBF out of the mix! I want to know what DNAP is going to do in the next 12 to 18 months? I said DNAP, the TBF connection is there and is not going away; therefore, we can all email Craig Hall and TBF and get those answers. The purpose of the top ten is and should be directed at the business plan and it's implementation! This is important information! That is one of the prime reasons for the open house! Our questions should be directed at getting substantive answers about DNAP's 2001 plan of action!
My opinion on this matter!
I hope you are right!!!
There is a lot of confusion about whether or not DNAP is planning a Reverse Split.
Below are 3 documents that should clear up this issue:
1. Nov 9 Email from IR saying there currently is NO intention of executing a RS.
2. July 25 PR stating the intention to perform a RS had been reversed.
3. July 11 merger agreement document stating the original intention to perform a RS
Subj: DNAPrint Genomics
Date: 11/9/2000 12:27:20 PM Central Standard Time
From: chall@tbfcorp.net (Craig Hall)
Reply-to: chall@tbfcorp.net (Craig Hall)
To: sockthestocks@sockthestocks.com
XXXXX,
When we originally acquired DNAPrint Genomics our intentions were to do a reverse split. We have hence changed our stance on the reverse split and stated our position in a press release. Again, a reverse split is not an option at this time. We would only consider a reverse split if it served to meet the requirements to facilitate NASDAQ listing or if it was required in conjunction with secondary funding by a Wall Street investment bank to propel the company to the next level. We have tried to be very clear on this point. Running a company is a dynamic process and requires constant reevaluation of the available options. It is important to remember that we have a vested interest in the company's success and have no reason do do anything that would harm the company nor its stock price.
Regards,
Craig Hall
Investor Relations
Link to the PR stating the intention to not do a Reverse Split:
July 25, 2000 - Catalyst Communications, Inc. (Pink Sheets: "CLYC") announced today that it is changing its name to DNAPrint genomics, Inc., and its symbol to "DNAP". The name and symbol change will become effective on July 26th, 2000. All future communications and securities filings will be made under this new name and symbol.
The Company has begun initial preparations to file its Form 10SB with the goal of becoming a reporting company under the provisions of the Securities Exchange Act of 1934, as amended, so it will be eligible to be quoted on the NASD's OTC Bulletin Board prior to year-end. The Company currently has no intentions of executing a reverse stock-split.
Link to the 8K filed on 11-3-200 containing a document dated 7-11-2000
AGREEMENT AND PLAN OF EXCHANGE (the "Agreement"), dated as of July 11, 2000, between Catalyst Communications, Inc., a Utah Corporation ("CLYC") and DNAPrint genomics, Inc., a Florida Corporation (the "Company") and all of the Shareholders of the Company whose names appear in Exhibit "A" hereto ("Shareholders"). WITNESSED: WHEREAS, the Shareholders represent that they are the legal and beneficial owners of all of the outstanding shares of capital stock of the Company; and WHEREAS, the Shareholders desire to exchange one hundred percent (100%) of the capital stock of the Company for shares of Common Stock of `CLYC' and `CLYC' desires to effect such exchange and purchase, all on the terms and conditions hereinafter set forth in such a manner that the exchange will constitute a tax-free reorganization pursuant to the provisions of Section 368(1)(B) of the Internal Revenue Code of 1986, as amended. NOW THEREFORE, in consideration of the premises and the mutual agreements and undertakings hereinafter set forth, the parties do hereby adopt said plan of reorganization, and, in order to consummate said plan, do hereby agree as follows: 1. DELIVERY OF SHARES OF THE COMPANY. The Shareholders agree to transfer and deliver to `CLYC', and `CLYC' agrees to acquire one hundred percent (100%) of the capital stock of the Company from the Shareholders as set forth in Exhibit "A" attached hereto and by this reference made a part hereof. 2. CONSIDERATION FOR TRANSFER OF SHARES. Upon closing, CLYC agrees to issue two million five hundred sixty thousand (2,560,000) post-reverse shares of its common stock, and fund Company in accordance with Exhibit "C" hereto. Upon the terms and subject to the representations and conditions set forth in such Agreement, `CLYC' agrees to deliver said shares to the Shareholders upon finalization of this Agreement. In addition, three million eight hundred forty thousand (3,840,000) post-reverse shares (The "Escrowed Shares") of CLYC common stock will be held in escrow for five (5) years, and will be released to the Shareholders based upon the terms, conditions and achievements set forth in Exhibit "D" attached hereto. CLYC anticipates a 1 for 30 reverse split of its securities within the next twelve (12) months from the date of this Agreement.
DNAPRINT ANNOUNCES FILING OF 8-K
stocktribe.com---Dallas, TX---Calgary, AB
SARASOTA, FL., Nov. 3, 2000 –DNAPrint genomics, Inc. (currently traded through the Pink Sheets under ticker symbol: ‘DNAP’) today announced that it has filed a complete form 8-k with the Securities and Exchange Commission (SEC) which provides detailed disclosure of the merger with SDE Holdings 1, Inc., including financial disclosures.
"We are pleased to have completed this filing which will facilitate the dissemination of complete information about the Company and its progress," stated Chief Scientific Officer Dr. Tony Frudakis. Dr. Frudakis added, "Upon completion of appropriate regulatory reviews, the Company intends to file its forms to trade on the NASD Bulletin Board.
ABOUT DNAPRINT GENOMICS, INC.
DNAPrint genomics, Inc. provides practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. On October 17th, the Company announced that it merged with a SEC 12g full reporting company, and expects to be trading on the OTC Bulletin Board within 30 days. The 12g merger did not cause the Company any dilution, and the share structure, trading symbol and name will all remain identically as they existed prior to the 12g merger. For more information about the company, please visit www.DNAPrint.com
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint’s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. These and other risk factors are discussed in the Company’s Form 8-k filed with the Securities and Exchange Commission on November 3, 2000. DNAPrint expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
stocktribe.com has not been compensated for this summary, nor do we hold a position in this company.
To unsubscribe, reply to this e-mail with the word "UNSUBSCRIBE" in the subject line.
Here is a picture of the SNPstream 25K machine DNAP purchased from Orchid! Click on site map, on the left hand panel, then click on products under the technology heading.
http://www.orchid.com./
Welcome guys! I am on RB ,SI and here! I read the Yahoo and CNBC boards from time to time!
DNAP3: I like the sound of your new handle! It has great potential!!!!lol
Welcome to all: Thanks for joing us!
Array design
The foundation for the PHENOMETM system is our unique DNA
databank and SNP database. Our DNA databank couples consent
qualified DNA samples with extensive biographical data for each
sample for broad application to many project types. Our SNP
database is a proprietary assemblage of heretofore unknown and
undocumented SNPs, focused on candidate genes and genetic
pathways known to be involved in a wide variety of biological
functions. Each SNP in our database is linked to 35 different
qualitative and quantitative variables for convenient clustering. Over
70% of the SNPs in our database have not yet been reported in the
literature and do not appear in public databases. When selecting a
custom array of SNPs for your high-throughput needs, we can use
medline accession number, gene names, author names, dates,
population frequencies, various key words (such as cancer,
prostate, xenobiotic) or nucleotide sequences as search subjects for
our database. The goal is to merge information content value with
function based selection routines.
If you’d like to discuss your particular needs with us further,
please contact us at 1877-DNA-FILE.
Copyright DNAprint genomics © 2000
Personalized Medicine and Pharmacogenomics
Doctors and pharmacists have long known that individuals respond
differently to the same drug. The reason for this is the underlying
genetic variability between individuals. Pharmacogenomics is the
study of drug interactivity against the backdrop of genetic variability
and most properly involves a consideration of complex genetics (a
good analogy to this system is the flux-balance model in E. Coli-
Schilling et al.,1999). Whereas one person may effectively and
safely metabolize a certain drug, another may metabolize the same
drug into a dangerous toxin. By evaluating drug response against
genotype, it will be possible to define genetic profiles which are
compatible with certain treatment regimens and those which are not.
In this way, a patient’s response to a drug can be accurately
predicted before the drug is prescribed. The idea of using a patient’s
genotype as a factor in deciding on treatment options is commonly
referred to as Personalized Medicine. Though today’s drugs are
approved and developed based on their performance in a large
population of people, medicine of the future will be evaluated and
prescribed as tailor made solutions for a particular patient’s needs.
Copyright DNAprint genomics © 2000
Our Aim
We intend to enable the application of human genomics to help
prevent, define and diagnose disease. We will do this by developing
a new high throughput informatics platform by which SNPs and
complex sets of SNPs can be holistically and comprehensively
associated with complex diseases and physical traits.
Our model is to license/partner our platform to generate 21st century
medicines, and enable personalized medical analysis. We will do
this through a combination of license/partnerships, hardware and
software placement and application service provider (ASP) based
models.
Copyright DNAprint genomics © 2000
About Us
DNAPrint genomics is a young e-biotech
company based in southwest Florida. We
are developing an informatics platform
system that will provide dynamic
solutions for disease gene discovery,
genetic predisposition and genetic
analysis testing. Our work has real-life
application to the germinating field of
Personalized Medicine and will help lay
the foundation for a brand-new area of
medical research called Phenomics.
The PhenomeSM platform system that we are developing will help
identify an individual predisposed to develop cancer before the
onset of illness so that lifestyles can be altered and/or preventative
measures taken. It will be used to identify individuals who are
incompatible with certain drug treatments before the drugs are
prescribed and damage is done. It will be used to tease out
important genetic determinants associated with complex genetic
diseases, so that drugs can be developed to target these genes.
Our aim is ambitious. By partnering our platform with
biotech/pharma, we will participate in the downstream profits
generated from pharmaceutical products our platform has enabled.
By marketing our platform directly to the public, we intend to make
comprehensive genotype screening solutions accessible to people
all over the world via the internet. Our system will enable a more
holistic approach to using genomics information to improve peoples
lives.
The patient of the future will have more information and power than
ever imagined. The human genome project, the internet and recent
technological advancements all contribute to make this possible, and
we intend to take advantage of these synergies to become the
primary conduit for the generation and distribution of personalized
genetic information.
Copyright DNAprint genomics © 2000
Advantages
As one of the first practitioners in the new field of Phenomics, we
hold distinct advantages.
Our advantages are:
1.We have developed and patented a proprietary biochemical
reagent (TruSeqTM) for high-throughput genetic analysis using
a DNA chip based or electrophoresis based platform
technology.
2.We are forming strategic alliances with other genomics and
pharmacogenomics companies, for access to raw materials and
intellectual property, lowering our R and D basis.
3.We are assembling a proprietary collection of LIMS (FEMSTM)
and heuristic software tools for a revolutionary data mining
process specially suited for Phenomics applications.
4.We are compiling unique SNP databases for target phenotypes
and diseases. Our proprietary data mining routines capitalize
on the newness of high-throughput genotyping technology and
the recent completion of the human genome project.
Copyright DNAprint genomics © 2000
PhenomixTMSNiP databases
We have developed unique and comprehensive SNP databases
through the use of proprietary data mining techniques. Our work has
so far resulted in two distinct databases, one for cancer
predisposition screening and the other for drug interactivity
screening. Our databases are fully annotated, and contain relevant
LocusLink, Medline, UniGene, Entrez, and PubMed information.
What makes our database even more unique is that it contains
flanking sequence 5’ and 3’ for each target SNP which enables rapid
application to microchip based screening platforms. The data and
annotation that we have compiled does not currently exist in any
NCBI or other public database, and we currently enjoy their
exclusive use.
Copyright DNAprint genomics © 2000
Technology
For high-throughput SNP analysis, we use Genetic Bit Analysis
(GBA). Using proprietary analytical and software tools with this
equipment, we can produce the massive data quantity and quality
necessary for comprehensive genetic analysis. We process genetic
profiles in DNA chip based format, at a rate of 1-5 per second. We
will analyze over 500,000 genotypes during the coming year.
For standard DNA testing we use PE Applied Biosystems Genetic
Analyzer machines. This machine is a capillary electrophoresis
machine which uses a robotic liquid handling system to process
reactions with a minimal of user intervention.
We employ our innovative and proprietary products with both pieces
of equipment.
SNiPdocTM
High-throughput SNP profiling-To help us with our bottom line, we
provide contract SNP profiling services to the drug development
community. We call this service our SNiPdocTM service, and it is
targeted towards pharmaceutical companies. Many pharmaceutical
companies are seeking to enter into the field of Pharmacogenomics.
This new field of study could have a dramatic impact on overall
health care costs in the future. Furthermore, by having access to
pharmacogenomics data, pharmaceutical companies can focus their
clinical trials on segments of the population that are genetically
receptive to the treatment. Experimental drugs can be targeted to
individuals of a particular genotype, and genetic variations shown to
underlie a poor-response to a trial drug could be used as a basis for
eliminating the non-responding segment of the trial population from
the study. In this way, pharmaceutical companies can reduce drug
trial failures and the costs associated with them. Contracting this
work out to service providers is a viable option for many smaller
pharmaceutical companies who do not have the volume of work
necessary to justify the price of the equipment and expertise. At
DNAPrint Genomics, we offer multiple patient ? multiple SNP
sampling matricies designed on a custom, semi-custom or
predefined basis. We can use our proprietary PhenomixM databases
of medically relevant SNPs (numbering in the thousands of SNPs at
present), or design chips for your application de-novo. We will work
with your scientists to develop the experiments from beginning to
end, that suit your needs, and we can handle your project from
blood/tissue or DNA starting points. Data handling will be
customized for each client; data can be deposited in our secure SNP
relational databases system offering you the option of accessing
your data over the internet. Alternatively, we can burn and
hand-delivered CDs to you. As we develop our data mining
algorithms, you will have access to some of the most revolutionary
SNP pattern finding tools available anywhere. Using smart
PhenomixSM could help you identify overlapping sets of genotypes
associated with various phenotypes and/or phenotypic responses,
which you might otherwise miss if you conducted your studies on
your own or through another less-specialized facility.